Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Roy S Herbst, Stanley R Frankel

Abstract

Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies. Oblimersen sodium is an antisense oligonucleotide compound designed to specifically bind to human bcl-2 mRNA, resulting in catalytic degradation of bcl-2 mRNA and subsequent decrease in bcl-2 protein translation. Both small cell and non-small cell lung cancer show baseline and inducible expression of bcl-2, which may contribute to resistance to therapy. Preclinical studies have shown that combining bcl-2 antisense with chemotherapy improves antitumor response, increases apoptosis of tumor cells, and increases survival. Preliminary data from a large international randomized trial in melanoma show a trend toward increased survival and significantly improved response rates and response duration when oblimersen is added to dacarbazine. Phase I studies in small cell lung cancer patients demonstrate that oblimersen can be combined with paclitaxel or carboplatin and etoposide. The combination of docetaxel and oblimersen has been shown to be feasible in Phase I studies and is currently undergoing evaluation in comparison with docetaxel alone as first-line salvage therapy in patients refr...Continue Reading

References

Jun 21, 1985·Science·Y TsujimotoC M Croce
May 1, 1995·British Journal of Cancer·G FontaniniG Bevilacqua
Jan 1, 1994·The Journal of Cell Biology·J C Reed
Apr 19, 1997·Lancet·A WebbZ Dziewanowska
Jul 16, 1997·Journal of the National Cancer Institute·A ZieglerU Zangemeister-Wittke
Jun 30, 1998·Virchows Archiv : an International Journal of Pathology·R SilvestriniG Ravasi
Apr 27, 1999·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·P P KotyM L Levitt
Aug 13, 1999·Genes & Development·A GrossS J Korsmeyer
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C Reed
Sep 6, 2000·Nature Medicine·C A SchmittS W Lowe
Nov 14, 2000·The American Journal of Pathology·J C Reed
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·I Lebedeva, C A Stein
Feb 8, 2002·Cell·Ricky W JohnstoneScott W Lowe
Jun 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C M RudinE E Vokes
Jun 28, 2002·Cancer Cell·Douglas R Green, Gerard I Evan
Aug 7, 2002·Antisense & Nucleic Acid Drug Development·Richard J KlasaStanley R Frankel
Sep 5, 2002·Nature Reviews. Cancer·Suzanne Cory, Jerry M Adams
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M RudinEverett E Vokes

❮ Previous
Next ❯

Citations

Mar 17, 2005·World Journal of Urology·Alan SoColleen Nelson
Jun 28, 2005·Journal of the American Society for Mass Spectrometry·Jan M Tromp, Stefan Schürch
Jan 18, 2006·Annual Review of Medicine·Chand Khanna, Lee J Helman
Oct 3, 2007·The Journal of Clinical Investigation·Sophie SunJohn D Minna
Jun 2, 2009·The European Respiratory Journal·E Brambilla, A Gazdar
Feb 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M RudinEverett E Vokes
Dec 4, 2013·Cancer Chemotherapy and Pharmacology·Anthony W TolcherRichard A Messmann
May 15, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J RomA Schneeweiss
Aug 2, 2007·Expert Opinion on Therapeutic Targets·Khaled Fernainy, Nabil Saba
Mar 11, 2005·Expert Review of Anticancer Therapy·Heather WakeleeChandra P Belani
Jun 1, 2007·Expert Opinion on Drug Discovery·Irene M Lagoja, Piet Herdewijn
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Mitsuo SatoJohn D Minna
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kristina Viktorsson, Rolf Lewensohn
Jan 11, 2005·The Journal of Pathology·D B Longley, P G Johnston
Jul 31, 2014·Protein & Cell·Shunbin XiongXuejun Jiang
Sep 11, 2007·Cancer Treatment Reviews·Daniela D RosaAhmad Awada
Jun 5, 2007·Critical Reviews in Oncology/hematology·David Michod, Christian Widmann
Mar 24, 2009·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·J BooneF J W Ten Kate
Jan 24, 2007·Journal of Neurochemistry·Leslie N Johnson-AnunaW Gibson Wood
Dec 9, 2004·Biochimica Et Biophysica Acta·Jeff CummingsCaroline Dive
Oct 20, 2005·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Alan Richardson, Stan B Kaye
Apr 19, 2005·Hematology/oncology Clinics of North America·Olwen Hahn, Ravi Salgia
May 24, 2005·Biochemical Pharmacology·Nathalie Dias, Christian Bailly
Apr 5, 2016·Journal of Cancer Research and Clinical Oncology·Abdul Shukkur EbrahimAyad Al-Katib
Oct 27, 2010·Molecular Oncology·Claudius MuellerVirginia Espina
Jul 15, 2006·Rapid Communications in Mass Spectrometry : RCM·Jan M Tromp, Stefan Schürch
Sep 13, 2007·The Journal of Clinical Endocrinology and Metabolism·Constantine S MitsiadesNicholas Mitsiades
Aug 7, 2019·International Journal of Molecular Sciences·Georg C Hutterer
Jan 5, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Weiwei KeZaiming Lu
Apr 4, 2021·International Journal of Molecular Sciences·Walter Douglas Fairlie, Erinna F Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2022 Meta ULC. All rights reserved